marstacimab (Hympavzi)
Jump to navigation
Jump to search
Indications
- prevention of bleeding in patients with hemophilia A & hemophilia B without inhibitors[1] (FDA-approved Oct 2024)
Dosage
Mechanism of action
- marstacimab targets the tissue factor pathway inhibitor
More general terms
References
- ↑ 1.0 1.1 Melville NA Hemophilia: Marstacimab Sustains Long-Term Bleeding Decrease. Medscape. June 28, 2024 https://www.medscape.com/s/viewarticle/hemophilia-marstacimab-sustains-long-term-bleeding-decrease-2024a1000c2a
- ↑ FDA News Release. Oct 11, 2024 FDA Approves New Treatment for Hemophilia A or B Product is First Non-Factor and Once-Weekly Treatment for Hemophilia B. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b